As the number of individuals with neurodegenerative disorders will continue to rise over the next several decades, the need to properly quickly identify and diagnose patients as early as possible becomes paramount. The field has shifted towards more biologic-based definitions to help understand where patients stand in their disease course, as well as to distinguish similarly-presenting disorders apart from each other. One way to facilitate that has been through the advent of technologic diagnostic assays, like Quanterix’s Simoa platform.